SEARCH

SEARCH BY CITATION

References

  • 1
    Burt VL, Whelton P, Rocella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995;25:305331.
  • 2
    Joint National Committee, National High Blood Pressure Education Program: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:24132446.
  • 3
    World Health Organization-International Society of Hypertension Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens. 1999;17:151183.
  • 4
    Yusuf S, Sleight P, Pogue J, et al. for the Heart Outcomes Prevention Evaluation Study Investigators (HOPE). Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145153.
  • 5
    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 1991;325:293302.
  • 6
    Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after MI: results of the Survival and Ventricular Enlargement Trial (SAVE). N Engl J Med. 1992;327:669677.
  • 7
    Lewis EJ, Huniscker LG, Bain RP, et al. for the Collabora Study Group. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:14561462.
  • 8
    Frances C, Noguchi H, Massie B, et al. Are we inhibited: renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med. 2000;160:26452650.
  • 9
    Giatras I, Lau J, Levey SS. Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease. A meta-analysis of randomized trials. Ann Intern Med. 1997;127:337345.
  • 10
    Sowers JR. Hypertension in type II diabetes: update on therapy. J Clin Hypertens. 1999;1:4147.
  • 11
    Izzo JL, Levy D, Black HR. Clinical advisory statement. Importance of systolic blood pressure in older Americans. Hypertension. 2000;35:10211024.
  • 12
    Bakris GL, Williams M, Dworkin L, et al. for the National Kidney Foundation Hypertension and Diabetes Executive committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646661.
  • 13
    Peterson JC, Adler S, Burkhart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754762.
  • 14
    Burnett JC. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens. 1999;17(suppl 1):S37S43.
  • 15
    Weber, M. Emerging treatments for hypertension and potential role for vasopeptidase inhibitor. Am J Hypertens. 1999;12(11 pt 2):139S147S.
  • 16
    Ferdinand KC, Saini RK, Lewin AJ, et al. Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone. Am J Hypertens. 2000:13(pt 2):138A.
  • 17
    Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA. 1997;277:12931298.
  • 18
    Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Group and Antihypertensive Agents. N Engl J Med. 1993;328:914921.
  • 19
    Wright JM, Lee CH, Chambers GK. Systemic review of antihypertensive therapies: does the evidence assist in choosing the first-line drug? CMAJ. 1999;161:2532.
  • 20
    Grossman E, Messerli FH, Goldbourt U. Does diuretic therapy increase the risk of renal cell carcinoma in women? Am J Cardiol. 1999;83:10901093.
  • 21
    Franse L, Pahor M, Di Bari M, et al. Hypokalemia associated with diuretic use in cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000;35:10251030.
  • 22
    Reid IR, Ames RW, Orr-Walker BJ, et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med. 2000; 109:362367.
  • 23
    Wel-Chi L, Delaney C, et al. Omapatrilat, a novel vasopeptidase inhibitor reduces blood pressure in normotensive subjects [abstract]. J Am Coll Cardiol. 1999;33:309A.
  • 24
    Brown NJ, Ray WA, Snowden M, et al. Black Americans have an increased rate of angiotensin-converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1991;60(5):813.
  • 25
    Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibition, omapatrilat and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 2000;356(9230):615620.
  • 26
    Prisant LM, Nuetel JM, Ferdinand KC, et al. Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks. J Natl Med Assoc. 1999;91:4048.
  • 27
    Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:19571963.